The last holdout—the only age group still waiting
After more than two years of pandemic, the United States stood on the threshold of extending COVID-19 vaccine access to its youngest and most unprotected children — the 18 million Americans under five who had remained outside the reach of any authorized shot. The White House, moving carefully between regulatory process and public readiness, set a hopeful target of June 21 for first doses, contingent on the FDA and CDC completing their reviews. It was a moment of institutional momentum meeting a quieter, more personal hesitancy — a reminder that the distance between a policy and its acceptance is often measured not in logistics, but in trust.
- Eighteen million children under five remain the only Americans without access to a COVID-19 vaccine, a gap the White House is racing to close before summer.
- The entire rollout hinges on two sequential regulatory approvals — FDA authorization and CDC recommendation — without which not a single dose will ship.
- States, pharmacies, and community health centers were cleared to begin placing federal orders on Friday, signaling that the government is betting on the timeline holding.
- An FDA expert panel is scheduled for June 15, with a potential CDC green light by June 17, leaving a narrow window to load and deliver doses over the Juneteenth weekend.
- Even as the machinery accelerates, a Kaiser Family Foundation survey reveals that only 18% of parents plan to vaccinate immediately, while 27% say they will not vaccinate their young children at all.
The White House was preparing for a milestone it had long anticipated: the vaccination of America's youngest children against COVID-19. On Thursday, coronavirus response coordinator Dr. Ashish Jha announced that, if regulators moved as expected, children under five could begin receiving shots as early as June 21 — though he was careful to frame the date as a best-case scenario rather than a certainty.
The 18 million children under five represented the last unvaccinated age group in the country, and the path to changing that required two sequential approvals. The FDA would need to authorize vaccines for children aged six months through four years, and the CDC would need to issue a formal recommendation. Only then would doses ship. An outside FDA expert panel was scheduled to meet June 15 to review the evidence, with a potential CDC advisory meeting to follow by June 17 — leaving a tight but plausible window to distribute doses over the Juneteenth weekend.
Both Pfizer-BioNTech and Moderna had applications under FDA review. Pfizer released preliminary trial data showing 80 percent efficacy against symptomatic infection in young children, drawn from a study of 1,678 participants aged six months to four years. Moderna had submitted its own two-dose application back in April.
Yet the logistical optimism existed alongside a more complicated social reality. A Kaiser Family Foundation survey found that only 18 percent of parents with children under five planned to vaccinate immediately, while 38 percent wanted to wait and see, and 27 percent said they would not vaccinate their young children at all. The White House was preparing to offer a vaccine that a substantial share of its intended recipients had already declined — a tension that no regulatory timeline could resolve on its own.
The White House was preparing for a moment it had been waiting for: the chance to vaccinate the youngest Americans against Covid-19. On Thursday, Dr. Ashish Jha, the president's coronavirus response coordinator, announced that if regulators moved as expected, the first shots could go into the arms of children under 5 as early as June 21. The machinery was already in motion. Starting Friday, states, pharmacies, and community health centers would be able to place orders with the federal government, readying themselves for a rollout that hinged on two critical approvals still pending.
The 18 million children younger than 5 represented the last holdout—the only age group in America for whom a Covid vaccine remained unavailable. But the path forward was conditional. Everything depended on the Food and Drug Administration authorizing vaccines for children 6 months through 4 years old, and on the Centers for Disease Control and Prevention issuing a recommendation for their use. Until both agencies signed off, no doses would ship. Jha was careful to frame the June 21 date as a best-case scenario, not a guarantee.
The regulatory timeline was tight but plausible. The FDA had already signaled it would review applications from Moderna and Pfizer-BioNTech, with an outside expert panel scheduled to meet on June 15 to discuss the evidence. If authorization came soon after, and if the CDC's own advisory panel could convene and issue guidance by June 17, doses could be loaded onto trucks over the long weekend anchored by Juneteenth and arrive at vaccination sites by the third week of June.
Pfizer and BioNTech had released preliminary trial data showing their vaccine was 80 percent effective at preventing symptomatic infection in young children, based on results from 1,678 participants aged 6 months to 4 years. The company had completed its formal application for emergency authorization by Wednesday. Moderna, meanwhile, had submitted its own application in April for a two-dose vaccine regimen, with doses spaced four weeks apart.
Yet beneath the logistical optimism lay a stubborn reality about parental sentiment. A Kaiser Family Foundation survey painted a picture of deep ambivalence. Only 18 percent of parents with children under 5 said they would vaccinate immediately. Thirty-eight percent fell into a "wait and see" posture, wanting more time or more information before deciding. And 27 percent said flatly that they would not vaccinate their young children at all. The White House was preparing to distribute a vaccine that a significant portion of the population it was meant to serve had already decided against.
The regulatory machinery would move forward regardless. The FDA panel was set to convene in less than two weeks. If the process unfolded as hoped, American parents would soon face a choice that had been unavailable to them for more than two years of the pandemic.
Citas Notables
Dr. Ashish Jha said doses could ship over the three-day weekend that includes Juneteenth and be available June 21, contingent on FDA and CDC authorization.— Dr. Ashish Jha, White House coronavirus response coordinator
La Conversación del Hearth Otra perspectiva de la historia
Why does the White House care so much about getting this done by late June specifically? Is there a political deadline?
Not really a political one. It's more about momentum and readiness. If the FDA and CDC both act by mid-June, you have a window to ship over a long weekend when the system isn't as congested. Miss that window and you're waiting another week. For a White House that's been managing the pandemic, showing you can move fast once approval comes matters.
But the survey data is striking—27 percent of parents say they definitely won't vaccinate. That's not a small number. Why push so hard if nearly a third of the target population has already decided no?
Because the other 45 percent haven't decided yet. The "wait and see" group is real, and they're watching. If vaccines are available, accessible, and the rollout looks smooth and safe, some of them will move. The 27 percent who've decided no—they're probably not changing their minds no matter what the White House does. But you can't let that paralyze you.
The trial data—80 percent efficacy—that's good, but is it good enough for parents who are already skeptical?
It's solid. But efficacy numbers don't move people who are already afraid or who've decided the risk-benefit calculation doesn't favor vaccination for their child. The data matters for credibility with regulators and with parents who are genuinely undecided. For the others, no number will be enough.
What happens if the FDA or CDC delays? If we don't hit June 21?
Then you're looking at early July at the earliest. The machinery doesn't run as smoothly without that long weekend. And politically, it looks like a stumble—you promised late June, you miss it. But medically, a few weeks doesn't change much. The real question is whether the vaccines work and whether parents trust them enough to use them.